Fmcna - Edmond East is a medicare approved dialysis facility center in Edmond, Oklahoma and it has 14 dialysis stations. It is located in Oklahoma county at 301 Katie Michelle Blvd, Edmond, OK, 73034. You can reach out to the office of Fmcna - Edmond East at (405) 341-9926. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fmcna - Edmond East has the following ownership type - Profit. It was first certified by medicare in February, 2011. The medicare id for this facility is 372581 and it accepts patients under medicare ESRD program.
Name | Fmcna - Edmond East |
---|---|
Location | 301 Katie Michelle Blvd, Edmond, Oklahoma |
No. of Dialysis Stations | 14 |
Medicare ID | 372581 |
Managed By | Fresenius Medical Care |
Ownership Type | Profit |
Late Shifts | No |
301 Katie Michelle Blvd, Edmond, Oklahoma, 73034 | |
(405) 341-9926 | |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
NPI Number | 1023317146 |
Organization Name | Fresenius Medical Care Edmond East |
Doing Business As | Fresenius Medical Care Edmond, Llc |
Address | 301 Katie Michelle Blvd Edmond, Oklahoma, 73034 |
Phone Number | (405) 341-9926 |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
NPI Number | 1801118245 |
Organization Name | Fresenius Medical Care Edmond East |
Doing Business As | Bio-medical Applications Of Oklahoma, Inc. |
Address | 301 Katie Michelle Blvd Edmond, Oklahoma, 73034 |
Phone Number | (405) 341-9926 |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that nephrologists always communicated and cared for them. | 64% | 67% |
Patients who reported that nephrologists usually communicated and cared for them. | 22% | 15% |
Patients who reported that nephrologists sometimes or never communicated and cared for them. | 14% | 18% |
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 72% | 60% |
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 14% | 26% |
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 14% | 14% |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 61% | 62% |
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 23% | 20% |
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 16% | 18% |
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 69% | 62% |
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 19% | 26% |
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 12% | 12% |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 84% | 80% |
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 16% | 20% |
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 77% | 68% |
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 16% | 20% |
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 7% | 12% |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
Dialysis patients with Hemoglobin data | 31 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 10 |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 65 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 548 |
Percentage of adult patients getting regular hemodialysis at the center | 98 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fmcna - Edmond East with elevated calcium levels.
Patients with hypercalcemia | 67 |
Hypercalcemia patient months | 572 |
Patients with Serumphosphor | 74 |
Patients with Serumphosphor less than 3.5 mg/dL | 8 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 21 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 29 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 26 |
Patients with Serumphosphor greater than 7 mg/dL | 17 |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 79 |
Patient months included in arterial venous fistula and catheter summaries | 431 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 66 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 17 |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 62 |
Hospitalization Rate in facility | 154 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 284.3 |
Hospitalization Rate: Lower Confidence Limit | 87.1 |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Fmcna - Edmond East were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 22.1 (As Expected) |
Readmission Rate: Upper Confidence Limit | 35.4 |
Readmission Rate: Lower Confidence Limit | 12.2 |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Fmcna - Edmond East get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | .22 (As Expected) |
SIR: Upper Confidence Limit | 1.06 |
SIR: Lower Confidence Limit | .01 |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Fmcna - Edmond East's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 57 |
Transfusion Rate in facility | 35.1 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 101.9 |
Transfusion Rate: Lower Confidence Limit | 13.8 |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at Fmcna - Edmond East lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 239 |
Mortality Rate in facility | 19.7 (As Expected) |
Mortality Rate: Upper Confidence Limit | 27.5 |
Mortality Rate: Lower Confidence Limit | 13.6 |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago
Davita - Renal Treatment Centers West, Inc. Location: 50 S Baumann Ave, Edmond, Oklahoma, 73034 Phone: (405) 330-6646 |
News Archive
Judith Tsui, a UW Medicine clinician specializing in addiction treatment, was seeing more and more patients she was treating for opioid-use disorder also using methamphetamines, a powerful, highly addictive stimulant that affects the central nervous system.
Screening a chemical library of 200,000 compounds, researchers at UT Southwestern Medical Center have identified two new classes that can be used to study and possibly manipulate a cellular pathway involved in many types of cancer and degenerative diseases.
A study investigating the function of the recently discovered enhancer RNA molecules may open new avenues for gene therapy. According to the study researchers, altering the production and function of these molecules could affect the expression of genes and, in consequence, possibly also the progression of various diseases.
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
› Verified 9 days ago